Mobbs B G, Johnson I E
Department of Surgery, University of Toronto, Canada.
J Steroid Biochem. 1987 Dec;28(6):653-62. doi: 10.1016/0022-4731(87)90394-3.
We have adapted a commercially available enzyme immunoassay for ER (ER-EIA) for use with nuclear extracts of breast carcinoma specimens, and have examined the data obtained in relation to the results from cytosolic ER-EIA and radioligand (DCC) assays and from DCC assays for PgR. In a series of 139 carcinoma specimens, we observed a very significant correlation between the cytosolic ER concentration as measured by the EIA and DCC methods, and also between the log10 of the concentration of ER in the cytosolic and nuclear fractions assayed by the ER-EIA method. The correlation between nuclear ER and cytosolic PgR was also highly significant, but not as close as for cytosolic ER. If 130 fmol ER/mg DNA was used as a "cut-off" point to discriminate between specimens "positive" and "negative" for ERN, there was 87% concordance in receptor status between ERN and cytosolic ER, and 79% concordance between ERN and cytosolic PgR. Forty-one percent of specimens were positive or borderline for both ERN and cytosolic PgR, and it is suggested that this receptor combination may be a valuable predictive factor in prognosis and response to hormonal treatment.
我们对一种市售的雌激素受体酶免疫测定法（ER-EIA）进行了改良，使其适用于乳腺癌标本的核提取物，并研究了所得数据与胞质雌激素受体酶免疫测定法和放射性配体（葡聚糖包被活性炭，DCC）测定法以及孕激素受体DCC测定法的结果之间的关系。在一系列139个癌标本中，我们观察到通过酶免疫测定法和DCC法测得的胞质雌激素受体浓度之间，以及通过雌激素受体酶免疫测定法测得的胞质和核部分中雌激素受体浓度的log10之间存在非常显著的相关性。核雌激素受体与胞质孕激素受体之间的相关性也非常显著，但不如胞质雌激素受体之间的相关性紧密。如果将130 fmol雌激素受体/毫克DNA用作区分雌激素受体核（ERN）标本“阳性”和“阴性”的“临界点”，则ERN与胞质雌激素受体之间的受体状态一致性为87%，ERN与胞质孕激素受体之间的一致性为79%。41%的标本ERN和胞质孕激素受体均为阳性或临界阳性，提示这种受体组合可能是预后和激素治疗反应的一个有价值的预测因素。
